NKGen Biotech (NASDAQ:NKGN) announced that results from its initial dose-escalation Phase 1 trial of troculeucel for the treatment of Alzheimer’s disease (AD) have been published in the international, peer-reviewed journal Alzheimer’s Research and Therapy.
According to NKGen, the publication provides key insights and further validates the findings from its Phase 1 study evaluating its expanded autologous NK cell therapy, troculeucel, in patients with mild to severe AD.
In a statement, Paul Y. Song, MD, chairman and CEO of NKGen, stated, “Previously presenting our positive findings at major medical conferences has been a great way to share our progress with the medical community, but having these data published in such a respected, peer-reviewed journal certainly elevates the credibility of our work and the importance of having a therapy such as troculeucel.”
Dr. Song added, “The rigorous peer-review process gives our research further validation, as it has been thoroughly evaluated by experts in the field, which not only strengthens the foundation of our early research but also highlights our potential to shape the future of AD treatment. Additionally, this is an important step towards advancing the scientific understanding of troculeucel as a potential treatment option for AD and other neurodegenerative diseases.”
